🚨 这就是持久治疗强化的样子。
@OncoAlert
在 #ESMO26 上，来自 III 期 PEACE-1 研究的长期随访显示，在初发 mCSPC 中，在标准治疗基础上加用阿比特龙 + 泼尼松，可在近 8 年后带来持续的生存获益。
📊 n=1,173 | 中位随访 7.7 年
➡️ OS HR 0.75 (0.65–0.87)
➡️ ADT + 多西他赛：中位 OS 6.2 对 4.4 年
➡️ 8 年 OS：40.3% 对 27.1%
而在大体积疾病中：
➡️ 8 年 OS：38% 对 20%
🎯 为什么这很重要：这不仅仅是一个早期延缓进展的信号。这是一个长期生存的故事。
对我来说，PEACE-1 强化了初发转移性 #ProstateCancer 中的一个重要原则：
当患者适合强化治疗时，延迟有效的全身治疗可能意味着失去无法在后期挽回的生存获益。
现在的挑战不再是证明强化治疗有效 —— 而是为合适的患者选择合适的三联方案，同时在毒性、合并症和可及性之间取得平衡。
来自 @RayMcDermott1 @BertrandTOMBAL 及 PEACE-1 研究者的重要长期数据。
点名 @neerajaiims @Silke_Gillessen @AOmlin @DrRanaMcKay @DrYukselUrun @declangmurphy @drenriquegrande @AmandaNizamMD @crisbergerot @nataliagandur
#OncoAlert #ESMO26 #mCSPC #mHSPC #TripletTherapy #GUOncology
313 浏览 · 9 赞 · 6 转发 · 0 回复
BNT324-03: A phase 3, randomized, open-label trial comparing elfetabart drozuntecan, a B7H3 antibody-drug conjugate, with investigator's choice of docetaxel or cabazitaxel in patients with metastatic castration-resistant prostate cancer
https://esmocongress.esmo.orgAnbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study
https://esmocongress.esmo.org- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
https://esmocongress.esmo.orgOncoAlert 4Sight Abstracts to be Presented at #ESMO26 Long-Term Overall Survival With Abiraterone Acetate Plus Prednisone in the PEACE-1 Phase 3 Trial for De Novo Metastatic Castration-Sensitive Prostate Cancer (mCSPC) @RayMcDermott1 @BertrandTOMBAL 🔬 Phase 3, 2×2 factorial (n=1173): abiraterone and/or prostate RT added to SOC (ADT ± docetaxel) in de novo mCSPC. Median follow-up 7.7 y. ➡️ Abiraterone: OS HR 0.75 (0.65–0.87); p=0.0001 ➡️ ADT + docetaxel ± abiraterone: median OS 4.4 vs 6.2 y; 8-year OS 27.1% vs 40.3% ➡️ High-volume: 8-year OS 20% vs 38%; interaction by metastatic extent p=0.56 ✅ Major OS benefit of adding abiraterone to SOC, irrespective of metastatic extent; triplet associated with almost twice as many long-term survivors in some subgroups. #ProstateCancer 🎙️ Karim Fizazi 👥 Stéphanie Foulon · Joan Carles · Guilhem Roubaud · Ray McDermott · Aude Fléchon · Bertrand Tombal · Stéphane Supiot · Dominik Berthold · Philippe Ronchin · Gabriel Kacso · Gwenaëlle Gravis · Fabio Calabro · Jean-François Berdah · Ali Hasbini · Marlon Silva · Antoine Thiery-Vuillemin · Igor Latorzeff · Loïc Mourey · Brigitte Laguerre · Sophie Abadie-Lacourtoisie · Etienne Martin · Claude El Kouri · Anne Escande · Alvar Rosello · Nicolas Magne · Friederike Schlurmann · Frank Priou · Marie-Eve Chand-Fouche · Salvador Villà Freixa · Muhammad Jamaluddin · Isabelle Rieger · Alberto Bossi (4Sight Made from Abstracts publicly available at the ESMO website) Pinging Our Faculty @DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper在 X 查看被引用的帖子
来源：Dra. María Natalia Gandur Quiroga · x.com